Primaquine

Primaquine

File:Primaquine.svg
Systematic (IUPAC) name
(RS)-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
Clinical data
Pregnancy category	?
Routes of administration	Oral
Legal status
Legal status	US: ℞-only Unlicensed (UK)
Pharmacokinetic data
Bioavailability	96%
Metabolism	Liver
Biological half-life	6 hours
Excretion	?
Identifiers
CAS Number	90-34-6
ATC code	P01BA03 (WHO)
PubChem	CID 6135
DrugBank	APRD00604
Chemical data
Formula	C15H21N3O
Molar mass	259.347 g/mol[[]]
(verify)

Primaquine (or primaquine phosphate) is a medication used in the treatment of malaria and Pneumocystis pneumonia. It is a member of the 8-aminoquinoline group of drugs that includes tafenoquine and pamaquine.

Indications

Radical cure

Primaquine is mainly used to treat the P. vivax or P. ovale malaria. Once the parasite has been eliminated from the bloodstream, the remaining hypnozoites must be removed from the liver and this is done by administering a 14 day course of primaquine. This process is called a radical cure.

If primaquine is not administered to patients with proven P. vivax or P. ovale infection, there is a very high likelihood of relapse within weeks or months (sometimes years).

When attempting a radical cure, primaquine requires the presence of quinine or chloroquine in order to work. If primaquine is given alone, the cure rate is only 21%. It is not known if other antimalarials such as mefloquine are likewise able to potentiate the effect of primaquine.

Primary prophylaxis

Primaquine is not routinely used to prevent malaria in travelers, and is only used as such when no other alternatives are appropriate. Primaquine is the recommended prophylactic agent by the Centers for Disease Control and Prevention (CDC) in some instances.

Terminal prophylaxis

Primaquine is also sometimes used presumptively to prevent malaria in people who have gone to areas where P. vivax or P. ovale are endemic (called terminal prophylaxis), but this controversial practice is not common outside of the U.S.

Pneumocystis pneumonia

Primaquine is also used in the treatment of Pneumocystis pneumonia (PCP), a fungal infection commonly occurring in people with AIDS and, more rarely, in those taking immunosuppressive drugs. To treat PCP effectively it is usually combined with clindamycin.

Adverse reactions

Side effects of primaquine administration include nausea, vomiting and stomach cramps. Other known adverse effects that occasionally occur are headache, visual disturbances and intense itching. Primaquine has also been shown to cause hemolytic anemia in people of African or Mediterranean descent; this was a plot point in the M*A*S*H episode "The Red/White Blues", in which Lebanese-American Max Klinger and Jewish-American Orderly Goldman developed anemia while taking primaquine, confusing the doctors who thought it was only a possibility if he were of African descent.

Primaquine causes methemoglobinemia in all patients who take it (levels of up to 18% are reported, normal level is <1%), but this seldom causes symptoms and is always self-limiting. Dangerous levels of methemoglobinemia only occur in patients with glucose-6-phosphate dehydrogenase deficiency.

Contraindications

Primaquine should not be administered to anyone with glucose-6-phosphate dehydrogenase deficiency because there can be a severe reaction with hemolytic anemia. Primaquine is contraindicated in pregnancy, because the Glucose-6-phosphate dehydrogenase status of the fetus would be unknown. Primaquine should not be given to patients with NADH methemoglobin reductase deficiency.

The packaging label states that primaqine should not be given to patients with systemic lupus erythematosus or rheumatoid arthritis, but the rationale behind this is questionable.

Dosing

Primaquine doses are always expressed as base, not as salt (15 mg base=26.3 mg phosphate salt).

Radical cure

• Plasmodium vivax: 30 mg once daily for 14 days (note that older authorities quote 15 mg instead);
• Plasmodium ovale: 15 mg once daily for 14 days.

The FDA licensed dose in the U.S. is 15 mg once daily, but this is not the dose recommended by the CDC for P. vivax; the FDA decision in 1952 to limit the primaquine dose to 15 mg was motivated by the fact that G-6-PD testing was not routinely available, 15 mg was known to be effective against the P. vivax strains found in Korea (in the US, the main use of primaquine at that time was to treat soldiers returning from war), and because 15 mg of primaquine is not likely to cause hemolysis in G-6-PD deficient patients. Primaquine is not licensed in the UK, but is available on a named-patient basis.

Primary prophylaxis

The dose of primaquine in primary malaria prophylaxis is 30 mg once daily, starting the day before travel and continuing for 7 days after returning. It needs only to be given for seven days after returning because primaquine is active against liver schizonts (the exoerythrocytic stages) and is therefore a causal prophylactic. In children, the dose is 0.6 mg/kg/day (the maximum daily dose is 30 mg).

Manufacturing and availability

Primaquine was first tested on humans during the Stateville Penitentiary Malaria Study in 1944. Primaquine was licensed for use in the USA by the FDA in 1952 and is available as a generic drug from a variety of manufacturers.

Primaquine is not licensed for use in the United Kingdom. It is available on a named patient basis only from certain pharmaceutical providers. Primaquine tablets available in the UK contain 7.5 mg primaquine base (13.2 mg phosphate salt). Primaquine tablets available in the U.S. contain 15 mg base (26.3 mg phosphate salt).

External links

• National Institute of Health
• AIDS Education Global Information System

de:Primaquin pt:Primaquina